Short answer: WHO prequalification and NAFDAC registration are not the same thing. WHO prequalification is a global quality-assurance pathway for selected medicines, while NAFDAC registration is Nigeria's legal authorisation to market a medicinal product in the country. The two can support one another, but neither automatically replaces the other.
The core distinction
WHO prequalification is designed to help countries, procurement agencies and donor-funded programmes identify medicines that meet a defined standard of quality, safety and efficacy. It is especially relevant for products used in high-priority public health programmes, for upstream supply chain assurance and for internationally recognised product quality pathways.
NAFDAC registration is different. It is the Nigerian regulator's legal decision on whether a product may be marketed and sold in Nigeria. It is built around Nigerian law, Nigerian market authorisation pathways, pharmacovigilance expectations and local compliance obligations. NAFDAC will not treat WHO prequalification as a substitute for local market authorisation or local post-marketing obligations.
What WHO prequalification is
The WHO Prequalification of Medicines Programme evaluates medicines for use in public health emergencies and in programmes where quality assurance is essential to procurement and supply. It focuses on product quality, manufacturing standards, evidence of safety and efficacy, and the consistency of documentation that supports global procurement and access decisions.
In practical terms, WHO prequalification can strengthen trust in a product for international procurement and can support a company that is already building global regulatory maturity. It is not a universal passport for market entry in Nigeria. Its value lies in demonstrating a level of quality and regulatory discipline that is widely recognised internationally.
What NAFDAC requires
NAFDAC requires a company to satisfy the legal and regulatory requirements that apply in Nigeria for the relevant product category. That includes the local registration pathway, product documentation, manufacturing quality systems, pharmacovigilance arrangements, reporting obligations and ongoing compliance after approval.
For many products, especially medicines being marketed in Nigeria, WHO prequalification may help a company prepare stronger dossiers and quality systems, but it does not waive the need for local authorisation, local pharmacovigilance architecture, or local compliance with NAFDAC guidance and approved labeling.
| Area | WHO Prequalification | NAFDAC Requirements |
|---|---|---|
| Primary purpose | Global quality and procurement assurance for selected medicines. | Legal approval and regulatory oversight for medicines in Nigeria. |
| Scope | Selected priority medicines and products relevant to public health programmes. | All products intended for marketing or distribution in Nigeria. |
| Authority | WHO-based assessment framework. | NAFDAC as the Nigerian regulator. |
| Market access | Supports procurement, donor confidence and international recognition. | Allows legal market entry and distribution in Nigeria. |
| Local obligations | Does not replace local regulatory duties. | Includes local registration, pharmacovigilance and post-market compliance. |
| Best fit | Global access and quality assurance pathways. | Commercial and regulatory access within Nigeria. |
Where the two frameworks overlap
They overlap most strongly on quality expectations, manufacturing standards, pharmacovigilance discipline and documentation quality. Companies with strong GMP, quality systems and regulatory record-keeping are usually in a better position to satisfy either framework.
That said, the two frameworks are not interchangeable. A dossier that passes one pathway may still need to be restructured, translated, refreshed or adapted to fit a Nigerian regulatory submission. WHO prequalification is a quality governance signal. NAFDAC registration is the regulatory permission to legally operate in Nigeria.
When it matters for companies
WHO prequalification is especially relevant when a product is intended for public health procurement, donor-funded programmes, or broader international markets. For many manufacturers, it can improve the integrity of their quality systems and make later country-level submissions easier to prepare.
For Nigerian companies, the more immediate issue is whether the product can be legally registered, marketed and monitored in Nigeria according to NAFDAC requirements. If a company is already running a strong pharmacovigilance system and quality management system, WHO prequalification may be a valuable strategic step. But it should be treated as a complement to local compliance, not a substitute for it.
Practical compliance checklist
- Confirm whether the product is in scope for WHO prequalification.
- Assess whether the local Nigerian registration is the first priority.
- Review the dossier structure and quality system readiness.
- Keep product quality, manufacturing and safety documentation aligned.
- Ensure pharmacovigilance procedures are documented and active.
- Prepare for local follow-up requests from NAFDAC.
- Maintain local pharmacovigilance reporting and case handling.
- Track change control, variations, and post-marketing updates.
- Monitor quality and safety information across markets.
- Use WHO prequalification as an international quality signal.
- Keep Nigeria-specific requirements visible in your governance plan.
- Map local obligations into a single compliance operating model.
What companies should do next
Companies should not treat WHO prequalification as a shortcut around local registration. The better approach is to use it as a strategic improvement layer: strengthen quality systems, align dossiers and safety data processes, and prepare internal teams for both international and local regulatory expectations.
If the product is intended for the Nigerian market, the first decision point remains whether the locally required registration and pharmacovigilance pathway is ready. If the product has broader public health or procurement ambitions, the WHO pathway can be layered on top as part of a wider market access strategy.
Frequently asked questions
Is WHO prequalification required for medicines sold in Nigeria?
No. WHO prequalification is not the legal mechanism that gives a medicine the right to be sold in Nigeria. The product still needs the appropriate local regulatory approval and compliance pathway under NAFDAC.
Does WHO prequalification speed up NAFDAC review?
It may help a company prepare a stronger dossier and quality package, but it does not automatically replace or shorten Nigeria's local regulatory process. The final market authorisation decision remains a NAFDAC decision.
Is WHO prequalification only for donors and public health programmes?
It is most visible in donor, procurement and public health contexts, but the underlying quality disciplines are useful for any company developing a stronger global regulatory profile. Its strategic value remains strongest where international procurement and public health programmes matter most.
Can a company rely on one framework and ignore the other?
No. The safer approach is to understand the two as complementary. WHO prequalification strengthens global quality assurance; NAFDAC remains the local authority for market entry, pharmacovigilance and regulatory compliance in Nigeria.
Need help aligning your product strategy with local and global requirements?
MedNova supports companies that need to prepare for local NAFDAC compliance, quality systems, pharmacovigilance readiness and market-entry planning.
Talk to our teamKey references
- World Health Organization. Prequalification of Medicines Programme. Accessed September 2026.
- National Agency for Food and Drug Administration and Control. Good Pharmacovigilance Practice Guidelines and related medicines regulatory guidance.
- NAFDAC and WHO guidance documents on product quality, registration and pharmacovigilance requirements in Nigeria.